USPTO Patent Application: CBD for SYNGAP1 Encephalopathy
Summary
The USPTO has published a patent application (US20260083758A1) from Harmony Biosciences Management, Inc. detailing methods for treating SYNGAP1 encephalopathy using transdermal cannabidiol (CBD). The application was filed on November 28, 2025, and published on March 26, 2026.
What changed
This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically application US20260083758A1, filed by Harmony Biosciences Management, Inc. The application describes methods for treating SYNGAP1 encephalopathy by administering cannabidiol (CBD) transdermally to a subject. The filing date was November 28, 2025, and the publication date is March 26, 2026.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in the treatment of SYNGAP1 encephalopathy and may be of interest to pharmaceutical companies, medical device manufacturers, and researchers in the neurology and rare disease space. Compliance officers should note this as a potential future product or therapeutic area.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF SYNGAP1 ENCEPHALOPATHY
Application US20260083758A1 Kind: A1 Mar 26, 2026
Assignee
Harmony Biosciences Management, Inc.
Inventors
Terri Sebree, John Messenheimer, Donna Gutterman
Abstract
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
CPC Classifications
A61K 31/658 A61M 21/02 A61P 25/08 A61P 25/28 A61M 2021/0077
Filing Date
2025-11-28
Application No.
19403384
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.